← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	921	+11	+1%	$21.7B
2	2 Charles River Laboratories CRL $14.4B	302	+2	+0.7%	$4.65B
3	3 DELISTED bluebird bio BLUE	241	+31	+15%	$5.17B
4	4 DELISTED CATALENT, INC. CTLT	241	+32	+15%	$4.43B
5	5 Sarepta Therapeutics SRPT $1.78B	190	+10	+6%	$1.44B
6	6 Precigen PGEN $2.64B	172	+18	+12%	$2.41B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	159	-6	-4%	$2.56B
8	8 DELISTED SANGAMO THERAPEUTICS INC SGMO	143	+25	+21%	$467M
9	9 PTC Therapeutics PTCT $4.98B	114	-1	-0.9%	$615M
10	SIOX 10 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	113	+16	+16%	$2.52B
11	11 Lineage Cell Therapeutics LCTX $232M	109	+13	+14%	$151M
12	12 Regenxbio RGNX $454M	86	+1	+1%	$448M
13	13 Atara Biotherapeutics ATRA $96M	85	0	0%	$360M
14	14 Intellia Therapeutics NTLA $1.6B	85	+9	+12%	$269M
15	BLCM 15 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	84	-12	-13%	$216M
16	ATHX 16 DELISTED Athersys, Inc. Common Stock ATHX	81	+5	+7%	$32.4M
17	17 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	78	+14	+22%	$922M
18	AGTC 18 DELISTED Applied Genetic Technologies Corporation AGTC	77	-12	-13%	$50.6M
19	ISEE 19 DELISTED IVERIC bio, Inc. Common Stock ISEE	77	-23	-23%	$56.5M
20	20 Abeona Therapeutics ABEO $249M	70	+12	+21%	$98.6M
21	21 DELISTED Adverum Biotechnologies ADVM	63	-12	-16%	$32.5M
22	22 Fate Therapeutics FATE $232M	60	+7	+13%	$86.2M
23	ADAP 23 DELISTED Adaptimmune Therapeutics ADAP	56	+7	+14%	$216M
24	24 Fortress Biotech FBIO $63.4M	54	+6	+13%	$28.8M
25	25 Voyager Therapeutics VYGR $124M	52	+5	+11%	$98.1M